Puma Biotechnology Reaches Deal With FDA On SPA For Phase III Trial Of PB272

News | 20 February 2013

• Print This

Puma Biotechnology Inc. (PBYI: Quote) announced that it has reached agreement with the U.S. Food and Drug Administration or FDA under a Special Protocol Assessment or SPA for the planned Phase III clinical trial of the company's lead drug candidate ...

Click on the link to read the full article at RTT News
(This link will open in a new window)